Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
July 07 2016 - 7:00AM
Business Wire
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company
committed to discovering, developing and commercializing both
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, coagulopathies and
disorders of the central nervous system, today announced that
Gregory A. Demopulos, M.D., chairman and chief executive officer,
will present at the Cantor Fitzgerald 2nd Annual Healthcare
Conference in New York next week. The presentation is scheduled for
Tuesday, July 12, 2016 at 10:45 a.m. EDT.
The presentation will be webcast. The live and archived webcasts
can be accessed on the “Events” page of the company’s website at
www.omeros.com.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to
discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system. Derived from its proprietary
PharmacoSurgery® platform, the company’s first drug product,
OMIDRIA® (phenylephrine and ketorolac injection) 1%/0.3%, was
broadly launched in the U.S. in April 2015 for use during cataract
surgery or intraocular lens (IOL) replacement to maintain pupil
size by preventing intraoperative miosis (pupil constriction) and
to reduce postoperative ocular pain. In the European
Union, the European Commission has approved OMIDRIA for
use in cataract surgery and lens replacement procedures to maintain
mydriasis (pupil dilation), prevent miosis (pupil constriction),
and to reduce postoperative eye pain. Omeros has five
clinical-stage development programs focused on: complement-related
thrombotic microangiopathies; complement-mediated glomerulopathies;
Huntington’s disease and cognitive impairment; addictive and
compulsive disorders; and preventing problems associated with
urologic surgical procedures. In addition, Omeros has a
proprietary GPCR platform, which is making available an
unprecedented number of new GPCR drug targets and corresponding
compounds to the pharmaceutical industry for drug development, and
a platform used to generate antibodies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160707005181/en/
Cook Williams Communications, Inc.Jennifer Cook Williams,
360-668-3701jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024